Clinical guideline
Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Ann Oncol · 2025
Studies and guidelines: Melanoma
28 items with a structured summary · Melanoma: the complete guide
Clinical guideline
European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma—update 2023
European Journal of Cancer · 2023
Clinical guideline
Screening for Skin Cancer
JAMA · 2023
Evidence insufficient to determine the balance of benefits and harmsResult of evidence assessment
Clinical guideline
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
CA A Cancer J Clinicians · 2017
To the nearest 0.1 mm (instead of 0.01 mm)Recording of tumour thickness
Other
Moderna’s new mRNA melanoma jab is making headlines, but experts urge caution
BMJ · 2026
Clinical trial · Phase 2/3
Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update
Eur J Cancer · 2025
30.6% vs 23.6%4-year progression-free survival
Clinical trial · Phase 3
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study
Eur J Cancer · 2025
71.3% vs 58.3%48-month recurrence-free survival
Clinical trial · Phase 3
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial
Eur J Cancer · 2024
50% vs 36%7-year recurrence-free survival
Review article
Cutaneous melanoma
The Lancet · 2023
Clinical trial · Phase 2
Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
N Engl J Med · 2023
72% vs 49%2-year event-free survival (landmark analysis)
Clinical trial
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
N Engl J Med · 2019
19%5-year progression-free survival
Clinical trial
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
N Engl J Med · 2018
13 of 26 patients (50%)Response rate in the phase 1 expansion cohorts
Clinical trial · Phase 3
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
N Engl J Med · 2017
86±1.3% in the dissection group vs 86±1.2% in the observation group3-year melanoma-specific survival (per-protocol analysis)
Clinical trial
Reduced Melanoma After Regular Sunscreen Use: Randomized Trial Follow-Up
JCO · 2011
11 vs 22 cases (HR 0.50; 95% CI 0.24–1.02)New primary melanoma (all cases)
Clinical trial · Phase 3
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
N Engl J Med · 2024
8.33 years (dabrafenib + trametinib) vs 6.87 years (placebo)Median duration of follow-up
Clinical trial · Phase 2b
Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study
J Clin Oncol · 2026
Hazard ratio 0.510Recurrence-free survival (RFS)
Clinical trial · Phase 3
Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma
N Engl J Med · 2025
24 events vs 65 events; HR for disease recurrence or death 0.32 (95% CI 0.20–0.51)Disease-free survival (events)
Clinical trial · Phase 3
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
N Engl J Med · 2025
71.9 / 36.9 / 19.9 monthsMedian overall survival
Clinical trial · Phase 3
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
N Engl J Med · 2024
83.7% vs 57.2%12-month event-free survival
Clinical trial · Phase 3
Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study
Ann Oncol · 2024
32.7 vs 15.9 monthsMedian overall survival
Clinical trial · Phase 3
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
N Engl J Med · 2022
7.2 vs 3.1 monthsMedian progression-free survival
Clinical trial · Phase 3
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609
JCO · 2020
HR 0.78 (repeated 95.6% CI 0.61–0.99)Overall survival: ipi3 vs HDI (intention-to-treat analysis of concurrently randomised patients, n=1,051)
Clinical trial · Phase 3
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
N Engl J Med · 2010
10.0 months vs 6.4 monthsMedian overall survival: ipilimumab + gp100 vs gp100 alone
Clinical trial · Phase 2b
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
Lancet · 2024
0.561Hazard ratio for recurrence or death (RFS)
Clinical trial · Phase 3
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
Lancet · 2022
11% vs 17%Recurrence or death (first interim analysis)
Clinical trial · Phase 2–3
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
N Engl J Med · 2022
10.1 vs 4.6 monthsMedian progression-free survival
Clinical trial · Phase 3
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
N Engl J Med · 2020
52% vs 36%Alive and relapse-free at 5 years
Clinical trial · Phase 3
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
N Engl J Med · 2018
75.4% vs 61.0%1-year recurrence-free survival (overall population)
Nothing found.